BG Klinikum Bergmannstrost, Halle, Germany Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2019
NCT03737461
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

BG Klinikum Bergmannstrost, Halle, Germany

Active Ingredients

Drugs in Phase 3 Trials (1)

allogeneic bone marrow derived mesenchymal stem cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 3)

Intervertebral Disc Degeneration (Phase 3)

Low Back Pain (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1